Skip to main content
. 2022 Jan 27;40(4):983–989. doi: 10.1007/s00345-022-03937-0

Fig. 1.

Fig. 1

EPI/PSA/PCPT/ERSPC score vs RP upgrading. Distribution scores of different parameter for patients with GG1 at biopsy who (1) remained GG1 post- RP, (2) were upgraded to GG2 post-RP, and (3) were upgraded to > GG3 post-RP for A EPI, ExoDx™ Prostate (IntelliScore) (p values for group comparisons shown in the figure); B PSA levels (Kruskal–Wallis rank sum test, p = 0.95 for comparison of all three groups); C PCPT risk calculator (Kruskal–Wallis rank sum test, p = 0.29); and D ERSPC risk calculator (one-way ANOVA, p = 0.76)